Tirzepatide, a novel treatment agent, has emerged as a groundbreaking innovation in the realm of GLP-1 receptor agonism. Unlike previous and wholesale BPC capsules GLP-1 receptor agonists, tirzepatide exerts its effects by simultaneously binding both the GLP-1 and GIP receptors. This dual mechanism of action promotes a substantial reduction in hype